Claims

[Claim 1]

A compound represented by general formula (I) or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof:



(I)

wherein each substituent is as defined below:

R^1: a C1-6 alkyl group, a C1-6 alkoxy C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group,

R^2: a hydrogen atom or a halogen group,

R^3: a hydrogen atom, a halogen group, a halogeno C1-6 alkyl group, a halogeno C1-6 alkoxy group, a C1-5 saturated cyclic amino group, a C1-6 dialkylamino group, a C3-6 cycloalkyl C1-6 alkoxy group, or a C1-6 alkoxy group,

A: a C3-6 cycloalkyl ring,

X: CH or N,

Y: CH or N,

Z: CH or N, and

n: an integer selected from 1, 2, 3, and 4.

[Claim 2]

The compound ~~according to claim 1~~ or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1, wherein the compound represented by the general formula (I) is a compound represented by general formula (I'):



(I')

[Claim 3]

The compound ~~according to claim 1 or 2,~~ or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 or 2, wherein R^1 represents a methyl group, an ethyl group, a methoxyethyl group, a cyclopropyl group, or a cyclopropylmethyl group.

[Claim 4]

The compound ~~according to any one selected from claims 1 to 3,~~ or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 3, wherein R^2 represents a hydrogen atom, a chlorine atom, or a bromine atom.

[Claim 5]

The compound ~~according to any one selected from claims 1 to 4,~~ or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 4, wherein R^3 represents a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a 2,2,2-trifluoroethoxy group, a pyrrolidin-1-yl group, a piperidin-1-yl group, a diethylamino group, a cyclopropylmethoxy group, or a methoxy group.

[Claim 6]

The compound ~~according to any one selected from claims 1 to 5,~~ or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 5, wherein A represents a cyclohexane ring.

[Claim 7]

The compound ~~according to any one selected from claims 1 to 6,~~ or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 6, wherein X, Y, and Z each represent CH.

[Claim 8]

The compound ~~according to any one selected from claims 1 to 7,~~ or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 7, wherein n is 2.

[Claim 9]

The compound ~~according to claim 1 or 2,~~ or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 or 2, wherein each substituent is any one selected from the following substituent groups:

R^1: a methyl group, an ethyl group, a methoxyethyl group, a cyclopropyl group, and a cyclopropylmethyl group,

R^2: a hydrogen atom, a chlorine atom, and a bromine atom,

R^3: a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a 2,2,2-trifluoroethoxy group, a pyrrolidin-1-yl group, a piperidin-1-yl group, a diethylamino group, a cyclopropylmethoxy group, and a methoxy group,

A: a cyclohexane ring,

X: CH and N,

Y: CH and N,

Z: CH and N, and

n: 2 and 3.

[Claim 10]

~~Any one~~The compound according to Claim 1, wherein the compound is selected from the following compound group ~~or a pharmacologically acceptable salt thereof~~:



, or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.

[Claim 11]

~~A~~ The compound according to claim 1, wherein the compound is represented by the following formula ~~or a pharmacologically acceptable salt thereof~~:



or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.

[Claim 12]

The ~~A~~ compound according to claim 1, wherein the compound is represented by the following formula ~~or a pharmacologically acceptable salt thereof~~:



or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.

[Claim 13]

The ~~A~~ compound according to claim 1, wherein the compound is represented by the following formula ~~or a pharmacologically acceptable salt thereof~~:



or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.

[Claim 14]

The ~~A~~ compound according to claim 1, wherein the compound is represented by the following formula ~~or a pharmacologically acceptable salt thereof~~:



or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.

[Claim 15]

The pharmacologically acceptable salt according to any one selected from claims 10 to 14, which is a dipotassium salt.

[Claim 16]

The pharmacologically acceptable salt according to any one selected from claims 10 to 14, which is a disodium salt.

[Claim 17]

The pharmacologically acceptable salt according to claim 15 or 16, which is a hydrate thereof.

[Claim 18]

The compound or pharmacologically acceptable salt thereof, or the hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 17 for use in therapy.

[Claim ~~18~~19]

A pharmaceutical composition comprising the compound or pharmacologically acceptable salt thereof, or the hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 17~~, or a pharmacologically acceptable salt thereof~~.

[Claim ~~19~~20]

The pharmaceutical composition according to claim ~~18~~19, which is used to inhibit the uptake of phosphorus.

[Claim ~~20~~21]

The pharmaceutical composition according to claim ~~18~~19, which is used to prevent or treat hyperphosphatemia.

[Claim ~~21~~22]

Use of the compound or pharmacologically acceptable salt thereof, or the hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 17 ~~or a pharmacologically acceptable salt thereof~~ for the production of a pharmaceutical composition for preventing or treating hyperphosphatemia.

~~[Claim 22]~~

~~Use of the compound according to any one selected from claims 1 to 17 or a pharmacologically acceptable salt thereof for the prevention or treatment of hyperphosphatemia.~~

~~[Claim 23]~~

~~A method for preventing or treating hyperphosphatemia, which comprises administration of an effective amount of the compound according to any one selected from claims 1 to 17 or a pharmacologically acceptable salt thereof.~~

[Claim 23]

The compound or pharmacologically acceptable salt thereof, or the hydrate of the compound or pharmacologically acceptable salt thereof, according to any one selected from claims 1 to 17 for use in the prevention or treatment of hyperphosphatemia.